A5088230440- Eosinophilic Esophagitis
- Eosinophilic Disorders and Syndromes
- Helicobacter pylori-related gastroenterology studies
- Gastroesophageal reflux and treatments
- Celiac Disease Research and Management
- Esophageal and GI Pathology
- Gastric Cancer Management and Outcomes
- Microscopic Colitis
- Gastrointestinal disorders and treatments
- Veterinary medicine and infectious diseases
- Gastrointestinal Bleeding Diagnosis and Treatment
- IL-33, ST2, and ILC Pathways
- Gastrointestinal Tumor Research and Treatment
- Microbial Metabolites in Food Biotechnology
- Gastrointestinal motility and disorders
- Radiopharmaceutical Chemistry and Applications
- Diagnosis and treatment of tuberculosis
- Intestinal and Peritoneal Adhesions
- Intestinal Malrotation and Obstruction Disorders
- Anesthesia and Sedative Agents
- Tracheal and airway disorders
- Hemostasis and retained surgical items
- Child Nutrition and Feeding Issues
- Galectins and Cancer Biology
- Colorectal Cancer Screening and Detection
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
2016-2024
Complejo Hospitalario de Cáceres
2020-2024
Centro de Investigación Biomédica en Red
2024
GTx (United States)
2014-2023
Instituto de Salud Carlos III
2021-2022
Hospital San Pedro de Alcántara
2012-2021
University Gastroenterology
2020
Hospital Universitario de La Princesa
2017
Hospital General de Tomelloso
2013-2016
Zamorano Pan-American Agricultural School
2015
Consensus diagnostic recommendations to distinguish GORD from eosinophilic oesophagitis (EoE) by response a trial of proton pump inhibitors (PPIs) unexpectedly uncovered an entity called 'PPI-responsive oesophageal eosinophilia' (PPI-REE). PPI-REE refers patients with clinical and histological features EoE that remit PPI treatment. Recent evolving evidence, mostly adults, shows at baseline are clinically, endoscopically histologically indistinguishable have significant overlap in terms Th2...
Background & AimsSwallowed topical-acting corticosteroids are recommended as first-line therapy for eosinophilic esophagitis (EoE). Asthma medications not optimized esophageal delivery sometimes effective, although given off-label. We performed a randomized, placebo-controlled trial to assess the effectiveness and tolerability of budesonide orodispersible tablet (BOT), which allows drug be delivered esophagus in adults with active EoE.MethodsWe double-blind, parallel study 88 EoE Europe....
The best approach for Helicobacter pylori management remains unclear. An audit process is essential to ensure clinical practice aligned with standards of care.International multicentre prospective non-interventional registry starting in 2013 aimed evaluate the decisions and outcomes H. by European gastroenterologists. Patients were registered an e-CRF AEG-REDCap. Variables included demographics, previous eradication attempts, prescribed treatment, adverse events outcomes. Data monitoring was...
Summary Background The molecular basis and effects of proton pump inhibitor ( PPI ) therapy on ‐responsive oesophageal eosinophilia ‐ REE eosinophilic oesophagitis (EoE) remain unknown. Aim To compare symptom‐histological cytokine gene expression in EoE patients, at baseline after specific treatment. Methods In consecutive adult patients with an phenotype (dysphagia/food impaction, typical endoscopic findings > 15 eos/ HPF ), eotaxin‐3, IL ‐13, ‐5 were determined distal proximal...
<h3>Objectives</h3> No trial has compared non-bismuth quadruple 'sequential' and 'concomitant' regimens in settings with increasing clarithromycin rates. The study aims to compare the effectiveness safety of these therapies for <i>Helicobacter pylori</i> treatment. <h3>Design</h3> Prospective randomised clinical 11 Spanish hospitals. Patients naïve eradication therapy non-investigated/functional dyspepsia or peptic ulcer disease were included. Randomised (1:1) sequential (omeprazole (20...
Proton pump inhibitor-responsive esophageal eosinophilia (PPI-REE) is diagnosed in at least one-third of patients with suspected eosinophilic esophagitis (EoE). We aimed to evaluate the durability and factors influencing long-term efficacy PPI therapy.Retrospective multicenter cohort study PPI-REE who had 12 months follow-up. therapy was tapered lowest dose, which maintained clinical remission. Primary outcomes were proportion loss histological response (<15 eos/HPF) predictors response....
Summary Background The most commonly used second‐line Helicobacter pylori eradication regimens are bismuth‐containing quadruple therapy and levofloxacin‐containing triple therapy, both offering suboptimal results. Combining bismuth levofloxacin may enhance the efficacy of rescue regimens. Aims To evaluate tolerability a regimen containing in patients whose previous H. treatment failed. Methods This was prospective multicenter study including whom standard ( PPI –clarithromycin–amoxicillin)...
Background Ultra-short coeliac disease (USCD) is defined as villous atrophy only present in the duodenal bulb (D1) with concurrent positive serology. We first, multicentre, international study of patients USCD. Methods Patients USCD were identified from 10 tertiary hospitals (6 Europe, 2 Asia, 1 North America and Australasia) compared age-matched sex-matched conventional disease. Findings (n=137, median age 27 years, IQR 21–43 years; 73% female) younger than those (27 vs 38 respectively,...
Proton pump inhibitor-responsive oesophageal eosinophilia (PPI-REE) is common in patients with suspected eosinophilic oesophagitis (EoE). However, the long-term efficacy of PPIs and best maintenance doses are yet to be defined.To evaluate durability response PPI therapy after tapering PPI-REE patients.Prospective study conducted on patients. Upon complete remission high-dose (omeprazole 40 mg b.d. for 8 weeks), were tapered followed by an endoscopic procedure each dose reduction. The primary...
Using quadruple clarithromycin-containing regimens for Helicobacter pylori eradication is controversial with high rates of macrolide resistance.To evaluate antibiotic resistance and the efficacy empirical tailored nonbismuth (concomitant) therapy in a setting cure <80% triple sequential therapies.209 consecutive naive H. pylori-positive patients without susceptibility testing were empirically treated 10-day concomitant (proton pump inhibitors (PPI), amoxicillin 1 g, clarithromycin 500 mg,...
Background Empiric triple therapy for Helicobacter pylori should be abandoned when clarithromycin resistance rate is >15–20%. Optimisation of (high-dose acid suppression and 14-day duration) can increase eradication rates by 10%. Aim To compare the efficacy safety optimised (OPT-TRI) nonbismuth quadruple concomitant (OPT-CON) therapies. Methods Prospective multicentre study in 16 Spanish centres using clinical practice. In a 3-month two-phase fashion, first 402 patients received an OPT-TRI...
Abstract Background Skin testing‐guided elimination diet has proved unsuccessful for adult eosinophilic oesophagitis ( E o ), whereas empiric six‐food SFED ) achieves an efficacy of 70%. Objective To compare the food‐specific serum I g ‐targeted sIgE ‐ ED and . Methods Prospective study in patients with Food‐specific , skin prick test SPT atopy patch APT to foods included were performed. Those ≥1 positive IgE test, defined by ≥0.1 kU/l, followed a 6‐week non‐IgE‐sensitized underwent SFED....